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Introduction: Nasal potential difference (NPD) test has long been used to assist in
the diagnosis of CF and more recently as an outcome measure in clinical trials of
new CF therapies. This test has also been adapted to the mouse nose.
Objectives: We aimed at evaluating variability of the NPD measurements in CF
patients displaying two severe CFTR mutations and in sex-matched healthy controls.
NPD recorded from F508del-CF and normal wild-type mice were also compared.
Methods: In each setting, tests were performed by a single qualiﬁed operator. In
the clinical setting, the latest CFTT-TDN SOP was followed. A total of 80 tracings
were obtained from 10 patients (23.2 y; range 14 to 32) and 10 healthy subjects
(34 y; range 24 to 53), each tested twice, in both nostrils. Two CF and two controls
were excluded from the statistical data analysis due to the presence of a single
non interpretable NPD tracing (4/80, 5%). To achieve equal sample size, tests
were obtained from 8 CF mice and normal wild-type. Comprehensive multivariate
analysis of paired data showed a good reproducibility of NPD parameters in
the clinical and the pre-clinical setting; lower variability was observed in mice.
However, 95% repeatability limits of NPD parameters were large indicating a large
measurement error, poor precision and low within-subject repeatability. In both
settings, chloride secretion was shown to be the most reproducible and repeatable
parameter.
Conclusion: In human as in mice, NPD showed good reproducibility but limited
between-subject repeatability.
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Objective: To assess the earliest CF-related signs and symptoms in participants of
a newborn screening program.
Methods: On the scheduled date of sweat test and immediately before sweat sample
collection, data on clinical history and physical examination were collected. CF
diagnosis was conﬁrmed by two sweat chloride measurements (60mEq/L). Cases
with meconium ileus were excluded.
Results: 41 cases (24.1%) with a positive and 129 controls (75.9%) with a negative
sweat test were included. Mean birth weight and mean age at the day of sweat test
were 3,131 g and 3,276 g (p = 0.04), and 34.2 and 34.4 days old (p = 0.88) for cases
and controls, respectively. Statistically signiﬁcant differences were obtained from
univariate analysis for weight gain lower than 300 g from birth up to the date of
sweat test (22.0% vs. 6.2%, OR= 4.2, p< 0.01), salty taste of the skin (43.9%
vs. 14.0%, OR= 4.7, p< 0.001), chest retractions (19.5% vs. 1.6%, OR= 14.9,
p< 0.001), and voracious appetite (31.7% vs. 12.4%, 1.3, p< 0.01). After logistic
regression, weight gain lower than 300 g (OR= 5.1, 95%CI, 1.6–15.6, p< 0.01),
salty taste (OR= 4.4, 95%CI, 1.8–10.7, p = 0.001), and chest retractions (OR= 8.1,
95%CI, 1.4–44.9, p = 0.01) remaining as independent predictors of CF diagnosis.
Conclusions:
1. moderate-severe CF can be clinically suspected in the ﬁrst weeks of life,
2. patients requiring treatment can be thus promptly identiﬁed and treated, and
3. in settings with or without newborn screening, children presenting the clinical
ﬁndings described above must be referred to sweat test (among other lab exams)
and/or offered a trial with pancreatic enzyme to conﬁrm or to rule out CF.
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Objective: To determine the extent to which hepatic ﬁbrosis is manifested in CF
children using Liver Ultrasound Elastography (LUE).
LUE is viewed as one of promising techniques for a non-invasive diagnosis of a
hepatic ﬁbrosis stage in CF patients. There is, however, insufﬁcient research data
about application of this technique in pediatric patients at this point.
Methods: 45 children with CF aged 3 to 17 years (average age of 8.3±3.7 years)
have been examined. All the children have been subjected to LUE using the
FibroScan device (EchoSens, France). 14 (31.1%) out of the 45 children have been
found to have abnormal median elasticity values ranging from 6.1 to 62.1 kPa. Of
them, values obtained from 6 (42.9%) patients have indicated liver cirrhosis (F4),
and 1 (7.1%) severe ﬁbrosis (F3), 2 (14.3%) − moderate (F2), and 5 (35.7%) − mild
ﬁbrosis (F1). In addition, out of the 45 children, LUE results from 15 (33.3%) have
varied widely: although all of them have shown normal median elasticity values,
some measurements have revealed elevated values, thus putting the patients in the
group at risk of developing diffuse liver ﬁbrosis.
Conclusions: According to LUE, 31.1% of the children with CF have ﬁbrotic
changes in the liver. Of them, 50% have severe ﬁbrosis and cirrhosis; Another 33.3%
of the patients are at risk of developing hepatic ﬁbrosis. LUE is an informative
non-invasive method of staging hepatic ﬁbrosis in CF children and can be applied
repeatedly to assess the rate at which the condition is progressing.
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Background: Diabetic retinopathy (DR) is a serious potential complication of
CFRD, and all such patients should undergo an annual screen for this, organized
in the UK through the primary care national Retinopathy Screening (RS) program.
However, some CFRD patients fail to attend for screening. We were interested to
assess patients’ understanding of DR, and the reasons for their non-attendance.
Method: Using a standardized questionnaire we asked 47 CFRD patients about
their understanding of DR, the importance of RS (Likert-scale 1−5), and their
compliance with screening.
Results: Eighty-one percent had heard about DR but only 45% admitted to formal
counseling. Only 64% had attended RS in the previous year: of these, 13% had
background changes and one patient (2%) had proliferative disease. Of those who
did not attend, 65% said they were not asked, 24% either forgot or did not rate this
an important appointment, and 12% had a recent CFRD diagnosis. Overall, 53%
rated RS as very important (Likert-scale 5), 32% Likert-scale 3 or 4 and 15% were
unsure.
Importance of RS perceived by patients
Likert scale Proportion of patients
1 (Least important) 0
2 0
3 15%
4 17%
5 (very important) 53%
Don’t know 15%
Conclusion: Our results show that a signiﬁcant number of CFRD patients are either
not aware or lack full understanding of DR, and many do not give RS enough
importance and subsequently fail to attend. We are reinforcing our RS education
program by providing literature at the CF annual screen and mailshots to CFRD
patients. Direct registration of patients to the national RS program may also help
improve the continuity of care.
